Drugs / pSG2.HIVconsv
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01151319 | Oct 2010 → Apr 2014 | HIV infectious disease | University of Oxford | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02425241 | Oct 2013 → Feb 2016 | HIV infectious disease | University College, London | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | pSG2.HIVconsv | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01151319 ↗ |
| Modality | Vaccine | “A Randomized Single-blind Placebo-controlled Study to Evaluate the Safety and Immunogenicity of Three Candidate HIV-1 Vaccines, pSG2.HIVconsv DNA, ChAdV63.HIVconsv and...” NCT01151319 ↗ |
| Route | Intramuscular | “3 intramuscular immunizations with an experimental DNA vaccine” PMID 29772028 ↗ May 2018 |